Anti-Mullerian hormone and associated pregnancy outcomes in females with polycystic ovary syndrome undergoing In vitro fertilization-embryo transfer

Jiacheng Du,Yuping Cao

doi:10.51441/biomedica/5-350

Jiacheng Du, Yuping Cao

Open Access

https://doi.org/10.51441/biomedica/5-350

Copy DOI

Journal: BioMedica	Publication Date: Dec 25, 2021
Citations: 1	License type: cc-by

Affiliation: Second People’s Hospital of Yibin

Abstract

Background and Objective: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women worldwide. Pregnancy in these women is highly affected by serum levels of Anti-Mullerian hormone (AMH). This study aimed to determine the association of serum AMH levels with pregnancy outcomes in females with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization-embryo transfer (IVF-ET) Methods: A total of 200 PCOS patients undergoing IVF-ET in the Reproductive Medicine Center, Second People's Hospital of Jingmen, China were included. The patients were divided into two groups, A and B, based on their AMH levels. Serum sex hormones levels and pregnancy outcomes in terms of fertilization, cleavage, implantation, high quality embryo and biochemical &nbsp;and clinical pregnancy rates were compared. Results: Mean age of the patients was 28.74&plusmn;2.07 years in group A and 29.74&plusmn;2.23 years in group B. Participants in group A had lower serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), and testosterone (T) compared to group B. Also, better pregnancy outcomes and lower frequency of pregnancy complications were seen in the participants of group A (P&lt;0.05). AMH serum levels showed high specificity and sensitivity in predicting IVF-ET clinical pregnancy in PCOS patients. Conclusion: Serum AMH levels in females with PCOS &nbsp;predict &nbsp;improved sex hormone profile and clinical pregnancy outcomes after IVF-ET

Highlights

Polycystic ovary syndrome (PCOS) is a relatively common endocrine and metabolic disorder in females of gestational age, characterized by symptoms, such as menstrual abnormalities, hirsutism, infertility, and acne.[1]
The infertility symptoms of PCOS patients are mainly due to their hyperandrogenemia, hyperinsulinemia and other diseases
Serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), and T in group A were significantly lower than group B (p < 0.05), while E2, P, and PRL serum levels in group A were not significantly different (p > 0.05)

Summary

Introduction

Polycystic ovary syndrome (PCOS) is a relatively common endocrine and metabolic disorder in females of gestational age, characterized by symptoms, such as menstrual abnormalities, hirsutism, infertility, and acne.[1]. The treatment is mainly oral anti-androgen active contraceptives or insulin sensitizers.[4] some patients have drug ineffectiveness and long-term infertility, and in vitro fertilization-embryo transfer (IVF-ET) is needed for fertility treatment.[5] IVF-ET mainly achieves conception through controlled superovulation, in vitro fertilization and transplantation after egg retrieval, but some patients have poor pregnancy outcomes.[6] At present, there is still a lack of clinically effective items to evaluate the pregnancy status and pregnancy outcome of patients with PCOS after IVF-ET. Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women worldwide Pregnancy in these women is highly affected by serum levels of Anti-Mullerian hormone (AMH). This study aimed to determine the association of serum AMH levels with pregnancy outcomes in females with PCOS undergoing in vitro fertilization-embryo transfer (IVF-ET)

Objectives

Methods

Results

Discussion

Conclusion